Compare Rion Co., Ltd. with Similar Stocks
Dashboard
1
Company has very low debt and has enough cash to service the debt requirements
2
Poor long term growth as Net Sales has grown by an annual rate of 6.19% and Operating profit at 13.14% over the last 5 years
3
Positive results in Dec 25
4
With ROE of 9.11%, it has a very attractive valuation with a 1.07 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 44,637 Million (Small Cap)
12.00
NA
0.00%
-0.24
9.11%
1.35
Revenue and Profits:
Net Sales:
6,932 Million
(Quarterly Results - Dec 2025)
Net Profit:
797 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
30.24%
0%
30.24%
6 Months
44.23%
0%
44.23%
1 Year
49.47%
0%
49.47%
2 Years
17.66%
0%
17.66%
3 Years
97.89%
0%
97.89%
4 Years
47.19%
0%
47.19%
5 Years
35.09%
0%
35.09%
Rion Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.19%
EBIT Growth (5y)
13.14%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.89
Tax Ratio
26.68%
Dividend Payout Ratio
30.15%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.82%
ROE (avg)
8.50%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.07
EV to EBIT
6.83
EV to EBITDA
5.09
EV to Capital Employed
1.09
EV to Sales
0.98
PEG Ratio
1.80
Dividend Yield
NA
ROCE (Latest)
15.98%
ROE (Latest)
9.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
6,932.40
7,449.70
-6.94%
Operating Profit (PBDIT) excl Other Income
1,447.80
1,630.50
-11.21%
Interest
0.50
0.60
-16.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
797.10
931.30
-14.41%
Operating Profit Margin (Excl OI)
155.80%
175.60%
-1.98%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is -6.94% vs 16.28% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -14.41% vs 25.14% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
27,877.90
25,727.00
8.36%
Operating Profit (PBDIT) excl Other Income
5,276.40
4,376.70
20.56%
Interest
2.20
1.90
15.79%
Exceptional Items
-164.70
-77.10
-113.62%
Consolidate Net Profit
2,859.80
2,652.40
7.82%
Operating Profit Margin (Excl OI)
144.70%
135.10%
0.96%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 8.36% vs 7.79% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 7.82% vs 47.39% in Mar 2024
About Rion Co., Ltd. 
Rion Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






